RxDoctor Payments Data

Ian Purcell, MD

Neurology · San Diego, CANPI 1124233739

Payments from drug & device makers

$37,162in general payments, 2019–2025

Across 2,030 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$3K
  • Amgen$2K
  • Biogen$2K
  • Lundbeck LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $22K from 54 others

What the payments were for

  • Food & beverage$36,90699%
  • Education$2561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)297$3,930
UCB, Inc.123$2,810
Amgen(2 entities)98$2,160
Biogen79$1,809
Lundbeck LLC56$1,489
Teva Pharmaceuticals USA, Inc.79$1,306
Novartis85$1,089
AstraZeneca(2 entities)36$1,046
Neurelis, Inc.68$1,031
Pfizer67$961
Scilex Pharmaceuticals Inc.65$911
Eisai Inc.41$815
Lilly USA, LLC64$813
CSL Behring38$647
Biohaven Pharmaceutical Holding Company Ltd.37$623
Harmony Biosciences LLC19$608
Vanda Pharmaceuticals Inc.25$585
Zyla Life Sciences, Inc.109$574
Biohaven Pharmaceuticals, Inc.29$573
SK Life Science, Inc.28$557
Neurocrine Biosciences, Inc.21$548
GE HealthCare21$538
Sanofi26$532
Boston Scientific12$527
Adamas Pharmaceuticals, Inc.36$516
Bristol Myers Squibb33$489
Takeda Pharmaceuticals U.S.A., Inc.25$480
Johnson & Johnson(2 entities)17$450
Supernus Pharmaceuticals, Inc.46$434
Abbott14$427
Mallinckrodt Hospital Products Inc.15$389
Acadia Pharmaceuticals Inc16$388
Genentech USA, Inc.15$379
TG Therapeutics, Inc.17$356
Livanova USA, Inc.13$337
Upsher-smith Laboratories LLC15$315
Octapharma USA, Inc.9$293
Sunovion Pharmaceuticals Inc.20$281
Tanabe Pharma America, Inc.12$241
Argenx US, Inc.7$236
Alnylam Pharmaceuticals Inc.11$228
Banner Life Sciences, LLC7$221
Curonix LLC3$219
Insightec,inc8$212
Bausch Health US, LLC13$204
Neurent Medical Limited2$193
Inspire Medical Systems, Inc.2$193
Jazz Pharmaceuticals Inc.8$192
Currax Pharmaceuticals LLC13$181
Avanir Pharmaceuticals, Inc.11$180
Otsuka America Pharmaceutical, Inc.8$166
Grifols USA, LLC10$166
Arbor Pharmaceuticals, Inc.10$162
Si-bone, Inc.2$153
Amneal Pharmaceuticals LLC10$151
Impel Pharmaceuticals LLC6$144
Axsome Therapeutics, Inc.6$131
Portola Pharmaceuticals, LLC2$119
E.r. Squibb & Sons, L.L.C.1$118
Stryker1$111

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,162 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$1,756,328
Medicare patients
2,477
Services billed
16,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$197,400
Memantine Hcl19$310
Gabapentin12$106
Donepezil Hcl13$46
Sodium Chloride0.9 % Sodium Chloride11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$647$197,40015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →